767 related articles for article (PubMed ID: 29290076)
1. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Wang S; He Q; Shuai Z
Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
6. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
7. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
Séauve M; Auréal M; Laplane S; Lega JC; Cabrera N; Coury F
Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364
[TBL] [Abstract][Full Text] [Related]
8. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
9. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
Poddubnyy D; Rudwaleit M
Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
[TBL] [Abstract][Full Text] [Related]
11. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.
Olivieri I; Fanizza C; Gilio M; Ravasio R
Clin Exp Rheumatol; 2016; 34(5):935-940. PubMed ID: 27385374
[TBL] [Abstract][Full Text] [Related]
13. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
14. Can we reduce the dosage of biologics in spondyloarthritis?
Olivieri I; D'Angelo S; Padula A; Leccese P; Nigro A; Palazzi C
Autoimmun Rev; 2013 May; 12(7):691-3. PubMed ID: 22940233
[TBL] [Abstract][Full Text] [Related]
15. Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials.
Ho A; Younis I; Le QA
Semin Arthritis Rheum; 2022 Jun; 54():151996. PubMed ID: 35339841
[TBL] [Abstract][Full Text] [Related]
16. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
19. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.
Zhao SS; Ermann J; Xu C; Lyu H; Tedeschi SK; Liao KP; Yoshida K; Moots RJ; Goodson NJ; Solomon DH
Rheumatology (Oxford); 2019 Nov; 58(11):2025-2030. PubMed ID: 31081033
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis.
de Winter JJ; van Mens LJ; van der Heijde D; Landewé R; Baeten DL
Arthritis Res Ther; 2016 Sep; 18(1):196. PubMed ID: 27586785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
